The Role of Cathepsin X in Infection With the Helicobacter Pylori
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01137942|
Recruitment Status : Unknown
Verified March 2010 by University Medical Centre Ljubljana.
Recruitment status was: Recruiting
First Posted : June 7, 2010
Last Update Posted : July 12, 2010
|Condition or disease||Intervention/treatment|
|Persistence of Infection With Helicobacter Pylori||Drug: clarithromycin, metronidazole, proton pump inhibitor|
|Study Type :||Observational|
|Estimated Enrollment :||14 participants|
|Observational Model:||Case Control|
|Official Title:||Helicobacter Pylori and Gastric Cancer - the Role of Cytokine Polymorphism, Cytokine Expression and Expression of TLR on Persistence of Helicobacter Pylori Infection and Development of Gastric Cancer.|
|Study Start Date :||November 2008|
|Actual Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||July 2010|
H. pylori eradication failure
Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
Drug: clarithromycin, metronidazole, proton pump inhibitor
appropriate dose of antibiotics and proton pump inhibitor
Other Name: No other names
- Evidence that cathepsin X influences on the eradication of Helicobacter pylori confirmed by lower expression of cathepsin X and cytokines in those patients. that can not eradicate Helicobacter pylori. [ Time Frame: 7 months after last participant included in the study ]The investigators assume that vast majority of patients, that have problems with eradication of Helicobater pylori, not caused by primary resistence to antibiotics, can not eradicate helicobacter because of inappropriate immune response. The investigators will measure cathepsin X (CTSX) expression and assume that those patients who have low concentrations of CTSX also have inappropriate immune response seen in low levels of cytokines. To treat such patients, you need to give them different and longer antibiotic therapy.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01137942
|Contact: Alojz Ihan, MD, PhDemail@example.com|
|Contact: Miha Skvarc, MDfirstname.lastname@example.org|
|Rogaska Slatina, Slovenia|
|Contact: Bojan Tepes, MD. PhD +386 (0) 3 819 14 11 email@example.com|
|Principal Investigator: Bojan Tepes, MD, Phd|
|Sub-Investigator: Miha Skvarc, MD|
|Study Director:||Alojz Ihan, MD, PhD||Institute of microbiology and immunology, Ljubljana, Slovenia|